

FINAL  
DRAFT

INTERNATIONAL  
STANDARD

ISO/FDIS  
10993-10

ISO/TC 194

Secretariat: DIN

Voting begins on:  
2021-06-17

Voting terminates on:  
2021-08-12

---

---

## Biological evaluation of medical devices —

### Part 10: Tests for skin sensitization

*Évaluation biologique des dispositifs médicaux —*

*Partie 10: Essais de sensibilisation cutanée*

iTeh STANDARD PREVIEW  
(standards.iteh.ai)

ISO/FDIS 10993-10

<https://standards.iteh.ai/catalog/standards/sist/c982269a-3558-43e0-b2ac-b5bcc1f412a3/iso-fdis-10993-10>

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

ISO/CEN PARALLEL PROCESSING



Reference number  
ISO/FDIS 10993-10:2021(E)

© ISO 2021

**iTeh STANDARD PREVIEW**  
**(standards.iteh.ai)**

ISO/FDIS 10993-10  
<https://standards.iteh.ai/catalog/standards/sist/c982269a-3558-43e0-b2ac-b5bcc1f412a3/iso-fdis-10993-10>



**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
CP 401 • Ch. de Blandonnet 8  
CH-1214 Vernier, Geneva  
Phone: +41 22 749 01 11  
Email: [copyright@iso.org](mailto:copyright@iso.org)  
Website: [www.iso.org](http://www.iso.org)

Published in Switzerland

# Contents

	Page
<b>Foreword</b> .....	<b>v</b>
<b>Introduction</b> .....	<b>vi</b>
<b>1 Scope</b> .....	<b>1</b>
<b>2 Normative references</b> .....	<b>1</b>
<b>3 Terms and definitions</b> .....	<b>1</b>
<b>4 General principles — Step-wise approach</b> .....	<b>3</b>
<b>5 Pretest considerations</b> .....	<b>4</b>
5.1 General.....	4
5.2 Types of material.....	4
5.2.1 Initial considerations.....	4
5.2.2 Ceramics, metals and alloys.....	4
5.2.3 Polymers.....	4
5.2.4 Biologically derived materials.....	4
5.3 Information on chemical composition.....	4
5.3.1 General.....	4
5.3.2 Existing data sources.....	5
<b>6 Skin sensitization tests</b> .....	<b>5</b>
6.1 Choice of test methods.....	5
6.2 Murine local lymph node assay.....	6
6.2.1 Principle.....	6
6.2.2 Test sample preparation.....	6
6.2.3 Animals and husbandry.....	6
6.2.4 Test procedure.....	7
6.2.5 Treatment groups.....	8
6.2.6 Determination of cellular proliferation and tissue preparation.....	8
6.2.7 Results and interpretation.....	9
6.2.8 Test report.....	9
6.3 Guinea-pig assays for the detection of skin sensitization.....	9
6.3.1 Principle.....	9
6.3.2 Choice of test sample concentrations.....	10
6.3.3 Induction.....	10
6.3.4 Challenge.....	10
6.4 Important factors affecting the outcome of the test.....	10
6.5 Guinea-pig maximization test.....	11
6.5.1 Principle.....	11
6.5.2 Test sample preparation.....	11
6.5.3 Animals and husbandry.....	11
6.5.4 Test procedure.....	12
6.5.5 Observation of animals.....	14
6.5.6 Evaluation of results.....	14
6.5.7 Test report.....	15
6.6 Closed-patch test (Buehler test).....	15
6.6.1 Principle.....	15
6.6.2 Test sample preparation.....	15
6.6.3 Animals and husbandry.....	15
6.6.4 Test procedure.....	16
6.6.5 Observation of animals.....	16
6.6.6 Evaluation of results.....	17
6.6.7 Test report.....	17
<b>7 Key factors in interpretation of test results</b> .....	<b>17</b>
<b>Annex A (normative) Preparation of materials for sensitization testing</b> .....	<b>19</b>

<b>Annex B (informative) Method for the preparation of extracts from polymeric test materials</b> .....	<b>21</b>
<b>Annex C (informative) Non-animal methods for skin sensitization</b> .....	<b>24</b>
<b>Annex D (informative) Background information</b> .....	<b>36</b>
<b>Annex ZA (informative) Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered</b> .....	<b>39</b>
<b>Annex ZB (informative) Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered</b> .....	<b>41</b>
<b>Annex ZC (informative) Relationship between this European standard and the General Safety and Performance requirements of Regulation (EU) 2017/745 aimed to be covered</b> .....	<b>42</b>
<b>Bibliography</b> .....	<b>44</b>

**iTeh STANDARD PREVIEW**  
**(standards.iteh.ai)**

[ISO/FDIS 10993-10](https://standards.iteh.ai/catalog/standards/sist/c982269a-3558-43e0-b2ac-b5bcc1f412a3/iso-fdis-10993-10)

<https://standards.iteh.ai/catalog/standards/sist/c982269a-3558-43e0-b2ac-b5bcc1f412a3/iso-fdis-10993-10>

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

This document was prepared by Technical Committee ISO/TC 194 *Biological and clinical evaluation of medical devices*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 206, *Biological and clinical evaluation of medical devices*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This fourth edition cancels and replaces the third edition (ISO 10993-10:2010), which has been technically revised.

The main changes compared to the previous edition are as follows:

- this document now contains a description of skin sensitization testing only;
- [Annex C](#) on non-animal methods for skin sensitization (formerly [Annex D](#)) has been updated;
- the testing for irritation is now described in ISO 10993-23.

A list of all parts in the ISO 10993 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at [www.iso.org/members.html](http://www.iso.org/members.html).

## Introduction

This document assesses possible contact hazards from chemicals released from medical devices, which may produce skin sensitization.

Some materials that are included in medical devices have been tested, and their skin sensitization potential has been documented. Especially for dental material, sensitizing properties were reported—see Reference [51]. Other materials and their chemical components have not been tested and may induce adverse effects when in contact with human tissue. The manufacturer is thus obliged to evaluate each device for potential adverse effects prior to marketing.

Traditionally, small animal tests are performed prior to testing on humans to help predict human response (background information is provided in Annex D). Since 2015, several *in chemico* and *in vitro* assays have been validated and organization for economic co-operation and development (OECD) test guidelines released to assess the skin sensitization potential of chemicals.[75][79][104] An overview of available alternative sensitization tests for neat chemical is given in Annex C. These test methods, each developed to address a specific key event, might not alone be sufficient to conclude on the presence or absence of skin sensitization potential of chemicals and considered in the context of integrated approaches such as integrated approaches to testing and assessment (IATA), combining them with other complementary information. Note that the *in vitro* and *in chemico* tests for skin sensitization (see Annex C) have so far been validated only for neat chemicals and not for medical devices. In order to apply these assays for the testing of skin sensitization potential of medical devices, their applicability needs to be ascertained.

Where appropriate, the preliminary use of *in vitro* methods is encouraged for screening purposes prior to animal testing. In order to reduce the number of animals used, this document presents a step-wise approach, with review and analysis of test results at each stage. It is intended that, for regulatory submission, sensitization study/studies be conducted using GLP or ISO/IEC 17025 as applicable to the respective country and comply with regulations related to animal welfare. Statistical analysis of data are recommended and used whenever appropriate. This document is intended for use by professionals, appropriately qualified by training and experience, who are able to interpret its requirements and judge the outcomes of the evaluation for each medical device, taking into consideration all the factors relevant to the device, its intended use and the current knowledge of the medical device provided by review of the scientific literature and previous clinical experience.

The tests included in this document are important tools for the development of safe products, provided that these are executed and interpreted by trained personnel.

This document is based on numerous standards and guidelines, including OECD Guidelines, US Pharmacopoeia and the European Pharmacopoeia. It is intended to be the basic document for the selection and conduct of tests enabling evaluation of dermal sensitization responses relevant to the safety of medical materials and devices.

# Biological evaluation of medical devices —

## Part 10: Tests for skin sensitization

### 1 Scope

This document specifies the procedure for the assessment of medical devices and their constituent materials with regard to their potential to induce skin sensitization.

This document includes:

- details of *in vivo* sensitization test procedures;
- key factors for the interpretation of the results.

NOTE Instructions for the preparation of materials specifically in relation to the above tests are given in [Annex A](#).

### 2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1:2018, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 10993-12, *Biological evaluation of medical devices — Part 12: Sample preparation and reference materials*

ISO 10993-18, *Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process*

### 3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 10993-1 and the following apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- IEC Electropedia: available at <http://www.electropedia.org/>
- ISO Online browsing platform: available at <https://www.iso.org/obp>

#### 3.1

##### **allergen**

sensitizer

substance or material that is capable of inducing a specific hypersensitivity reaction upon repeated contact with that substance or material

#### 3.2

##### **allergic contact dermatitis**

clinical diagnosis based on an observed immunologically-mediated cutaneous reaction to a substance

3.3

**blank**

extraction *vehicle* (3.17) not containing the *test material* (3.15), retained in a vessel identical to that which holds the test material and subjected to identical conditions to which the test material is subjected during its extraction

Note 1 to entry: The purpose of the blank control is to evaluate possible confounding effects due to the extraction vessel, vehicle and extraction process.

3.4

**challenge**

process following the *induction* (3.8) phase, in which the immunological effects of subsequent exposures in an individual to the inducing material are examined

3.5

**elicitation**

immunological reaction to exposure to a sensitizer in a previously sensitized individual

3.6

**erythema**

reddening of the skin or mucous membrane

3.7

**extract**

liquid that results from extraction of the *test sample* (3.16) or control

[SOURCE: ISO 10993-12:2012]

ITeH STANDARD PREVIEW  
(standards.iteh.ai)

3.8

**induction**

process that leads to the *de novo* generation of an enhanced state of immunological activity in an individual, after initial exposure to a specific material

ISO DIS 10993-10  
standards/sist/c982269a-3558-43e0-b2ac-b5bcc1f412a3/iso-fdis-10993-10

3.9

**irritant**

agent that produces *irritation* (3.10)

3.10

**irritation**

localized non-specific inflammatory response to single, repeated or continuous application of a substance/material

Note 1 to entry: Skin irritation is a reversible reaction and is mainly characterized by symptoms like local *erythema* (3.6) (redness), swelling, itching, peeling, cracking and scaling of the skin.

3.11

**negative control**

well-characterized material or substance that, when evaluated by a specific test method, demonstrates the suitability of the procedure to yield a reproducible, appropriately negative, non-reactive or minimal response in the test system

Note 1 to entry: In practice, negative controls include *blanks* (3.3), *vehicles* (3.17)/solvents and reference materials.

[SOURCE: ISO 10993-12:2012 — modified, Note 1 to entry has been added.]

3.12

**oedema**

swelling due to abnormal infiltration of fluid into the tissues



**3.13****positive control**

well-characterized material or substance that, when evaluated by a specific test method, demonstrates the suitability of the test system to yield a reproducible, appropriately positive or reactive response in the test system

**3.14****skin sensitization**

T-cell mediated delayed-type hypersensitivity reaction induced by low molecular weight reactive chemicals (allergens). It comprises two phases, induction and elicitation

Note 1 to entry: In humans, the responses can be characterized by pruritis, *erythema* (3.6), *oedema* (3.12), papules, vesicles, bullae or a combination of these. In other species the reactions can differ and only erythema and oedema can be seen.

**3.15****test material**

material, device, device portion or component thereof that is sampled for biological or chemical testing

**3.16****test sample**

material, device, device portion, component, *extract* (3.7) or portion thereof that is subjected to biological or chemical testing or evaluation

**3.17****vehicle**

liquid used to moisten, dilute, suspend, *extract* (3.7) or dissolve the test substance/material

iTeh STANDARD PREVIEW  
(standards.iteh.ai)

**4 General principles — Step-wise approach**

ISO/FDIS 10993-10

The available methods for testing sensitization were developed specifically to detect skin sensitization potential. Other types of adverse effects are generally not predicted by these tests.

This document requires a step-wise approach, considering that any stage can result in the conclusion that further testing for skin sensitization is not necessary:

- a) Literature and supplier information review, including chemical and physical properties, and information on the sensitization potential of any medical device constituent as well as structurally-related chemicals and materials; refer to ISO 10993-1 for details. Conduct risk assessment based on existing information to determine whether sensitization risk is acceptable or whether further testing is necessary;
- b) Additional characterization and risk assessment, if needed, of the device material, involving chemical characterization and analysis of the test sample according to the general principles described in ISO 10993-18;
- c) *In vitro* tests shall be considered in preference to *in vivo* tests in accordance with ISO 10993-2, and the replacement of the latter as new *in vitro* tests are scientifically validated and become reasonably and practicably available;

NOTE There are currently a number of internationally validated and accepted *in vitro* tests to detect the skin sensitization potential of chemicals; however, these *in vitro* tests are not yet validated for medical devices. Work is ongoing for some of these tests to qualify them [SE031] for use with medical devices;

- d) *In vivo* animal tests are only appropriate when test materials cannot be characterized and risk assessments cannot be undertaken using information obtained by the means set out in a), b) and c).

## 5 Pretest considerations

### 5.1 General

It is important to emphasize that pretest considerations can result in the conclusion that testing for sensitization is not necessary.

The requirements given in ISO 10993-1:2018, Clause 5, and the following apply.

*In vivo*, non-sterile samples shall be investigated by topical investigation only, as the possibility of microbial contamination of the test sample could confound the final assay interpretation. In cases where the sterility of a test sample cannot be guaranteed, but the sample is still considered to be free from microbial contamination, intradermal administration may be justified.

### 5.2 Types of material

#### 5.2.1 Initial considerations

It shall be taken into consideration that during manufacture and assembly of medical devices, additional chemical components may be used as processing aids, e.g. lubricants or mould-release agents. In addition to the chemical components of the starting material and manufacturing process aids, adhesive/solvent residues from assembly and also sterilant residues or reaction products resulting from the sterilization process may be present in a finished product. Whether these components pose a risk depends on the leaching or degradation characteristics of the finished products. Those chemical components which have skin sensitization potential shall be identified.

#### 5.2.2 Ceramics, metals and alloys

These materials are normally less complex than polymers and biologically derived materials in terms of the number of chemical constituents.

#### 5.2.3 Polymers

The chemical composition of these materials is typically more complex than those in 5.2.2. A number of reaction products/impurities/additives/residual catalyst can be present and the degree or extent of polymerization can vary.

#### 5.2.4 Biologically derived materials

These materials are inherently complex in their composition. They often also contain process residues, for example, cross-linkers and anti-microbial agents. Biological materials can be inconsistent from sample to sample.

The methods in this document have not been designed for testing of biologically derived materials and can therefore be less adequate. For example, the tests in this document do not consider cross-species sensitization.

## 5.3 Information on chemical composition

### 5.3.1 General

Full qualitative data on the chemical constituents of the material shall be established. Quantitative data on the chemical composition shall also be obtained. If quantitative data are not obtained, the rationale shall be documented and justified.

### 5.3.2 Existing data sources

Qualitative and quantitative information on the composition shall be obtained where possible from the supplier of the starting material.

For polymers, this often requires access to proprietary information; provision should be made for the transfer and use of such confidential information.

Qualitative information about any additional processing additives (e.g. mould-release agents) shall also be obtained from appropriate members of the manufacturing chain, including converters and component manufacturers.

If information on composition is incomplete, a literature study to establish the likely nature of the starting material and any additives is recommended, so as to assist in the selection of the most appropriate methods of analysis for the material concerned.

The chemical composition of finalized products shall be determined in accordance with ISO 10993-18.

**NOTE** The composition of ceramics, metals and alloys can be specified in accordance with ISO or ASTM international standards and/or can be specified by the user. However, in order to obtain full qualitative and quantitative details on composition, it can be necessary to request these from the supplier or manufacturer of the starting material and also from component manufacturers to ensure that processing aids are also identified. Material master files held by regulatory authorities are another source of data, where they are accessible.

## 6 Skin sensitization tests

iTeh STANDARD PREVIEW

### 6.1 Choice of test methods (standards.iteh.ai)

*In vitro* and *in chemico* alternative approaches have been developed for neat chemicals using a combination of different assays to identify skin sensitizers. Several of these methods have been included in the OECD test guidelines (TG 442C[75], TG 442D[79] and TG 442E[104]) or in the OECD test guideline program<sup>[121]</sup> (see [Annex C](#)). b5bcc1f412a3/iso-fdis-10993-10

Together, the assays described in these test guidelines cover three key events of the now identified adverse outcome pathway (AOP) for sensitization, including the molecular initiating event (protein binding), induction of inflammation, and activation of dendritic cells. These test methods developed to address a specific key event may not alone be sufficient to conclude on the presence or absence of skin sensitization potential of chemicals and should be considered in the context of integrated approaches such as IATA, combining them with other complementary information.

In accordance with ISO 10993-2, such integrated approaches shall be taken into consideration for assessing skin sensitization potential of neat chemicals. Whether these approaches are also applicable for medical devices or medical device extracts is not (yet) known. An overview of available alternative sensitization tests for neat chemicals is presented in [Annex C](#).

There are currently three animal assays available for the determination of the skin sensitizing potential of chemicals. These include two guinea-pig assays and one murine assay. The two guinea-pig assays are the guinea-pig maximization test (GPMT) and the closed-patch test (Buehler test). Of these two assays, the maximization test is the most sensitive method. See Reference [9]. The closed-patch test is suitable for topical products.

The murine local lymph node assay (LLNA) was internationally accepted as an OECD test guideline in 2010<sup>[33]</sup> for testing single chemicals as a stand-alone alternative to the guinea-pig assays, and is now the preferred *in vivo* assay for chemicals. See References [19] and [32]. In some instances, guinea-pig assays can be necessary for the evaluation of the sensitizing potential of certain test samples. Such might be true in the case of certain metals (see Reference [44]) that may give false negative findings in the LLNA or skin irritants that may give false positive findings, as well as high molecular weight

substances, which do not penetrate the skin or substances that are not soluble in the recommended vehicles.

NOTE All three animal assays were developed for the detection of skin sensitizing potential of chemicals, i.e. contact dermatitis, delayed type (type IV) hypersensitivity.

In view of the provisions laid down in ISO 10993-2 on animal welfare requirements, when an *in vivo* assay is performed, the LLNA shall be taken into consideration. In addition to animal welfare considerations, the LLNA has the advantage of providing objective quantitative data.

## 6.2 Murine local lymph node assay

### 6.2.1 Principle

Following topical treatment of a test sample on the dorsum of the ears, the extent of lymphocyte proliferation is measured in the lymph nodes that drain the sites of application (ears). A response in cellular proliferation of threefold or more compared with the activity of the controls is the threshold for designating a test material as a sensitizer.

The LLNA shall be performed using a dose response approach when substances are used. For final products/medical devices, it can be sufficient to test only the undiluted extract.

NOTE References [15] to [44] contains representative LLNA publications. Laboratories conducting this assay are encouraged to review these and other relevant publications available.

### 6.2.2 Test sample preparation

The test sample shall be a liquid, suspension, gel or paste such that it can be applied to the ears of the mice. Where possible, a series of doses (dilutions) shall be investigated. Otherwise, the highest concentration prepared as a chemical solution or suspension or as an extract should be used. When a strong response in the LLNA is detected with an extract, a follow-up study evaluating multiple doses may be necessary to evaluate the possible sensitization potency of the extract. Systemic toxicity and excessive local skin irritation can invalidate the test results; these reactions should therefore be avoided. In certain circumstances, pre-testing can be necessary.

A commonly used vehicle for substances/chemicals is an acetone olive oil (AOO) 4:1 mixture. Liquid samples that are hydrophilic and/or do not adequately adhere to the skin of the ear should be modified to adhere to the test site. This can be obtained by adding a thickening agent like carboxy methyl cellulose or hydroxyethyl cellulose (with a density of 0,5 %) or by a surfactant such as Pluronic® L92<sup>1)</sup> with a volume fraction of 1 %. For water soluble chemicals, dimethyl sulfoxide (DMSO) or dimethyl formamide (DMF) are preferred above the surfactant Pluronic® L92. See Reference [34]. Alternatively, other extract vehicles can be used, as mentioned. See Reference [33]. The effect of additions to the extract media and/or changes in vehicle composition shall be validated and documented. This might be done by experiments using weak to moderate sensitizers as commonly used as positive control. In addition, spiking of the test sample with a positive control might be performed in order to demonstrate that the LLNA is still able to detect the presence of potential sensitizers in the prepared extract. Other fundamental aspects of test article extraction are specified in ISO 10993-12.

A separate extract shall be prepared for each daily application.

NOTE For polymeric materials, an optional extraction method is given in [Annex B](#).

### 6.2.3 Animals and husbandry

Healthy female non-pregnant mice of the CBA/Ca, CBA/J or BALB/c strain shall be used, unless another strain is validated. See References [33], [41] and [42]. Several mouse strains have been reported as

---

1) Pluronic® L92 is an example of a suitable product available commercially. This information is given for the convenience of users of this document and does not constitute an endorsement by ISO of this product.

acceptable (DBA/2, B6C3F1). See Reference [35]. The mice shall be 7 weeks to 12 weeks of age; the mice in each study shall be matched in age (within a one-week age range).

Husbandry and selection of animals shall be in accordance with ISO 10993-2. The mice, routinely acclimatized to the laboratory, shall be individually identified. For certain test samples, individual housing can be necessary. This shall be justified and documented.

Animals shall be uniquely identified by methods not to include ear punches or ear tags.

When group housing is performed, cross contamination and unwanted oral intake should be taken into consideration.

#### 6.2.4 Test procedure

For chemicals, the LLNA is generally performed in a dose-response manner. For solid medical devices, samples to be tested shall be extracts. In these cases, only a single dose is available for testing. In general, the extract can be investigated undiluted. However, when the extract contains highly toxic components, this can result in a negative response in the LLNA due to toxicity. It is therefore recommended, to perform the LLNA in a dose-response manner and to dilute the extract when investigating cytotoxic extracts (see ISO 10993-5). In addition, when a strong response is detected in the LLNA, a dose response follow up can be conducted to evaluate the possible sensitization potency of the extract.

In order to ensure reproducibility and sensitivity, a test of a positive-control substance for skin sensitization shall be included by the testing laboratory in order to validate the test system and demonstrate a positive response. Well-known weak to moderate contact allergens, e.g. mercaptobenzothiazole, hexyl cinnamic aldehyde, or benzocaine, shall be used as positive control. The examples mentioned might not be suitable for each vehicle used for sample preparation (e.g. water-based vehicle); in such cases, another positive control might be selected. ASTM F2148 indicates that in such circumstances formalin and 2,4-dinitrochlorobenzene (DNCB) should be used as positive controls. This shall be justified and documented. [ISO/FDIS 10993-10](https://standards.iteh.ai/catalog/standards/sist/c982269a-3558-43e0-b2ac-050cc1412a3/iso-10993-10)

While inclusion of a concurrent positive control group is recommended, there may be situations in which only periodic testing (i.e. at intervals  $\leq 6$  months) of the positive control test substance may be adequate. This is the case for laboratories that conduct the LLNA regularly (i.e. conduct the LLNA at a frequency of no less than once per month) and have an established historical positive control database that demonstrates the laboratory's ability to obtain reproducible and accurate results with positives controls. Adequate proficiency with the LLNA can be successfully demonstrated by generating consistent positive results with the positive control in at least 10 independent tests conducted within a reasonable period of time (i.e. less than one year).

The individual body weights shall be recorded at initiation and at the end of the study. In order to detect potential toxicity of the test sample, clinical observation shall be performed and recorded during the study.

Using a positive control only once every six months can have consequences for the results obtained in the previous six months period when this positive control shows a negative outcome. Reference [33] states that periodic testing (i.e. at intervals  $\leq 6$  months) of the positive control substance can be considered in laboratories that conduct the LLNA regularly, i.e. conduct the LLNA at a frequency of no less than once per month, and that have a history and a documented proficiency for obtaining consistent results with positive controls. It is important to realize that the decision to only include a positive control periodically instead of concurrently could have ramifications on the adequacy and acceptability of negative study results generated without a concurrent positive control during the interval between each periodic positive control study. For example, if a false-negative result is obtained in the periodic positive control test, all negative test substance results obtained in the interval between the last acceptable periodic positive control test and the unacceptable periodic positive control test could be questioned. In order to demonstrate that the prior negative test substance results are acceptable, a laboratory could be expected to repeat all negative tests, which would require additional expenses and increased animal use.



### 6.2.5 Treatment groups

When the LLNA is performed, the data of a minimum of five mice per group shall be available for evaluation. Lymph node responses may be determined either by individual measurement or by measurement of pooled lymph node samples. For statistical analysis, individual measurement is preferred.

When only a single dose is available for evaluation, for example, an extract, a minimum of five mice shall be used for each group, when individual responses are measured.

Treatment groups shall be assigned to:

- blank of each type of vehicle employed (see [Annex A](#));
- when appropriate, positive control for each vehicle employed;
- test groups for each extract vehicle employed.

When testing a single chemical or substance, the LLNA shall be performed in a dose-response manner. For other types of test and sample-like extracts, a dose-response evaluation might not be feasible. When only one test group is employed, this shall be justified and documented.

**NOTE** When sufficient data have been collected to demonstrate consistency for the dose response of the positive control, a single dose might be included to demonstrate the sensitivity of the assay. See Reference [32].

The appropriate sample shall be applied to the dorsal side of both ears of designated mice at a dose of 25  $\mu$ l/d for three consecutive days. Each day, observe the ears for signs of irritation that might interfere with interpreting results. See References [23], [27] and [29].

### 6.2.6 Determination of cellular proliferation and tissue preparation

The proliferating cells in the draining lymph nodes can be labelled by either a radioactive or fluorescent label. Radiolabels commonly used are  $^3$ H-methyl thymidine, and  $^{125}$ I-iododeoxyuridine, while for fluorescence, fluorodeoxyuridine might be used.

At (72  $\pm$  2) h after the last treatment, record individual mouse weights and administer intravenously the label for cell proliferation. Inject 0,25 ml of phosphate buffered saline (PBS) containing 740 KBq (20  $\mu$ Ci) units of radioactivity of  $^3$ H-methyl thymidine into all test and control mice via the tail vein. For  $^{125}$ I-iododeoxyuridine, inject 0,25 ml PBS containing 74 KBq (2  $\mu$ Ci), and for fluorodeoxyuridine inject 0,25 ml containing  $10^{-5}$  mol/l into the tail vein. See Reference [33].

Other alternative procedures not requiring radiolabelling are available and should be considered [e.g. adenosine triphosphate (ATP) (OECD TG 442A [122]) determination (DA method), bromodeoxyuridine BrdU (OECD TG 442B [123]) determination (ELISA or FCM method)].

**NOTE 1** For more information, see References [33], [36], [42], [43] and [49].

Euthanize the mice (5  $\pm$  0,75) h after the administration of the labelling solution according to ISO 10993-2. Remove the draining auricular lymph node. Care shall be taken to avoid cross contamination of the tissue samples. The lymph nodes of each group may be pooled, or pairs of lymph nodes of each individual animal may be pooled. Data from each individual animal is preferred as it provides the variability between each animal in a group. Single cell preparations are prepared by gently pressing the lymph nodes through a 200  $\mu$ m stainless steel wire mesh or nylon mesh over a container. Rinse the strainer with chilled PBS into the container to remove cells from the mesh filter. The container now contains the cell preparation. Cell preparations are washed twice by centrifugation and resuspended in PBS. Cells are precipitated with 5 % trichloroacetic acid (TCA) at (4  $\pm$  2)  $^{\circ}$ C for (18  $\pm$  1) h. After a final centrifugation, step pellets are resuspended in 1 ml of TCA and transferred to scintillation vials

containing 10 ml of scintillation fluid for  $^3\text{H}$ -counting, or transferred directly to a gamma counter for  $^{125}\text{I}$ -counting. See Reference [21], [35] and [36].

NOTE 2 Alternatively, labelling and determination of cellular proliferation can be performed *ex vivo*. See References [37] and [38].

### 6.2.7 Results and interpretation

Measure the level of radioactivity in the lymph node cells in counts per minute per mouse (cpm/mouse). Convert counts per minute (cpm) to disintegration per minute (dpm). Calculate the mean and standard deviation of dpm for at least three counts for each animal or each group of mice. Subtract the background value from each result.

When using the individual sampling method continue to calculate the mean and standard deviation of the dpm for each group of five mice. Determine the stimulation index (SI) by dividing the mean test dpm by the blank dpm. An SI of three or more ( $\geq 3,0$ ) shall be considered positive for designating a test sample as a sensitizer. See Reference [16].

Positive control samples shall produce an SI that is greater than or equal to 3,0.

For a valid study, the positive control shall be conducted either concurrently or within the previous six months. See Reference [33].

### 6.2.8 Test report

The test report shall include:

- a) a description of the test material(s) or device;
- b) the intended use/application of the test sample or material;
- c) the International Standard used (including its year of publication);
- d) a detailed description of the method employed in preparing the test sample or test material or device;
- e) a description of the test animals;
- f) method of application to the ears;
- g) description of method for determining cellular proliferation;
- h) any deviations from the procedure;
- i) records of the observations, including clinical and body weight observations;
- j) assessment of the results, including positive control;
- k) the date of the test.

## 6.3 Guinea-pig assays for the detection of skin sensitization

### 6.3.1 Principle

The two guinea-pig assays currently used for the detection of sensitizing activity of chemicals and medical devices are the Buehler assay and the GPMT. Both assays consist of an induction and challenge phase, thus covering all stages of hypersensitivity.